

## **ENROLLMENT AND BENEFITS VERIFICATION FORM**

FAX COMPLETED FORM TO 1-844-628-3299 • FOR ASSISTANCE, CALL 1-866-424-6935 ENROLL ONLINE AT UCBNAVIGATE.COM OR E-PRESCRIBE TO CAREFORM PHARMACY (NPI #1043762750)



PATIEN	T INFORMA	TION													
*Name (First, Middle Initial, Last)							*Gender assigned at birth Male Female				male	*DOB /	/		
*Street Address													Weight		
*City *State *										*Patient Email Address					
*Primary Phone # Alternate Phone #							Preferred Language English				nglish Spanish	ch Spanish Other			
Authorized Representative Contact Name								Authorized Representative Contact Phone #							
*INSURANCE INFORMATION Front and back copies of the patient's medical and pharmacy insurance card(s) attached No Insurance															
Primary Prescription Insurance Prescription Insurance Phone #															
Rx Member ID#				*Rx BIN #	*Rx P	*Rx PCN #						*Rx Group #			
Primary Me	dical Insurance			Phone #	#				Medical Insurance ID #			Medical Insurance Group #			
PRESCR	IBER INFOR	MATION													
*Prescriber (First, Midd	Name le Initial, Last)									*NPI#			*Tax ID #		
Office Con	tact					*Phone #				*Fax #					
*Practice/Clinic Name							Prescriber Email								
Street Address City									State	e		Zip Code			
Supervising Physician								NPI #							
CLINICAL INFORMATION															
*Primary Diagnosis Code   PSO						15 her:	Diagnosis:								
Outer							ONI ARIA® STELARA® TALTZ®				XELJANZ®				
Contraindications, or Intolerances (Select all that apply)  OTEZLA®  COSENTYX®			YX® SKYRIZ	® SII	SILIQ®			DMARD None			Other:				
Please Provide: PA/Appeal support Bridge/Savings support <sup>†</sup> (for eligible patients only)															
I have sent this prescription to:															
PRESCR	RIPTION INF	ORMATIC	ON												
INDICATION	INITIAL Inject 320 mg	REFILLS	MAINTENANCE			REFILL	S								
PSO	Inject 320 mg subcutaneously at week 16 and then every:  every 4 weeks at weeks 0, 4, 8, and 12  Inject 320 mg subcutaneously at week 16 and then every:  8 weeks <b>OR</b> 4 weeks may be considered if weight ≥ 120 kg					BIMZELX 160 mg/mL x 2 Autoinjector NDC 50474-781-85 BIMZELX 160 mg/mL x 2 Prefilled Syring NDC 50474-780-79						d Syringes			
PsA	\$\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Inject 160 mg/mL subcutaneously even			very 4 weeks							MZELX 16 DC 50474	<b>60 mg/mL x 1 Prefille</b> I-780-78	d Syringe	
PsA with PSO	Inject 320 mg subcutaneously every 4 weeks at weeks 0, 4, 8, and 12  Inject 320 mg subcutaneously at week 8 weeks OR 4 4 weeks may be considered if weight			·	·	BIMZELX : NDC 5047				60 mg/mL x 2 Autoinjector BIMZELX 160 mg/mL x 2 Prefilled 4-781-85 NDC 50474-780-79				d Syringes	
nr-axSpA or AS	Inject 160 mg/mL			subcutaneously ev		BIMZELX 160 mg/mL x 1 Autoinjector NDC 50474-781-84  BIMZELX 160 mg/mL x 1 Prefilled Syrin NDC 50474-780-78					d Syringe				
By signing below, I certify: 1) The therapy is medically necessary and that this information is accurate to the best of my knowledge; 2) I am disclosing this information to UCB, their affiliates, agents, representatives business partners, and service providers (together, "UCB") to help enable treatment for this Patient; 3) The Patient is aware of, has consented to, and has directed my disclosure of their information to UCB so that UCB may contact the Patient to further enable services for those purposes and that such consent and direction applies to disclosures made through the duration of the Patient's therapy; 4) I will not seek reimbursement from any third party for the support UCB provides; 5) I am licensed to prescribe the prescription medication identified in this form; 6) the prescription complies with my state-specific prescribing requirements, and appoint UCB as my agent for the limited purpose of conveying this prescription by any means under applicable law only to the dispensing pharmacy; and 7) I hereby authorize UCB's patient support program vendor to submit this Enrollment Form to the dispensing pharmacy as my signature. I understand that by signing this form, I am requesting support from UCB for the above-referenced patient who has been prescribed BIMZELX PRESCRIBER SIGNATURE: PRESCRIBER MUST MANUALLY SIGN AND DATE. RUBBER STAMPS AND SIGNATURE BY OTHER OFFICE PERSONNEL FOR THE PRESCRIBER WILL NOT BE ACCEPTED.															
RESCRIBE		nt unable t	o provide consen	t. Please send	d digital red	quest t	o obta	in Patie	ent A	uthorization	on to Use/Disc	lose H	lealth Informa	tion.	
GNATURE EQUIRED DISPENSE AS WRITTEN				— OR —	OR SUBSTITUTION PERM				N PERMITTE	:D		*Date Signe	d		

Please follow your state's prescribing guidelines for electronic prescriptions (if applicable). Please see accompanying Important Safety Information, refer to the full Prescribing Information provided by the UCB representative, and visit BIMZELXhcp.com.

CA, MA, NC, & PR: Interchange is mandated unless prescriber writes "No Substitution." ATTN: NY and IA, please submit electronic prescription.

## PATIENT AUTHORIZATION TO USE/DISCLOSE HEALTH INFORMATION

FOR BIMZELX® (bimekizumab-bkzx)



By signing this Patient Authorization to Use/Disclose Health Information form ("Authorization"), I hereby authorize each of my physicians, pharmacists (including any specialty pharmacy that receives my prescription for a UCB medication), and other of my healthcare providers (together, "Providers") and each of my health insurers (together, "Insurers") to disclose information related to my medical condition and treatment (including prescription information), my health insurance coverage and policy number, my name, mailing and email addresses, telephone number, and date of birth (together, "Health Information"), to UCB, Inc. and its agents, service providers, contractors, and representatives (together, "UCB"). My Health Information will be shared with UCB so that UCB may: (i) enroll me in, and contact me about, patient support programs and/or related market research for UCB medications; (ii) provide me with educational materials and information related to UCB medications; (iii) verify, investigate, assist with, and coordinate my coverage for a UCB medication with my Insurers and Providers; (iv) determine my eligibility for and help me access savings, interim care and/or free drug programs for UCB medications; (v) conduct market research and/or analyses or other commercial activity, including aggregating my Health Information with other data for such analyses; (vi) assist with analysis related to quality, efficacy, and safety for UCB medications; (vii) de-identify my Health Information for use for any purpose under applicable law.

I understand that I do not have to sign this Authorization and choosing not to sign will not affect my ability to receive treatment from my Providers or payment from my Insurers. However, if I do not sign this form, UCB may not be able to provide me with certain patient support. Once my Health Information has been disclosed to UCB, I understand that federal privacy laws may no longer protect this information. However, I understand that UCB and other parties authorized to receive my Health Information pursuant to this Authorization agree to protect my Health Information by using and disclosing it only for purposes authorized in this Authorization or as required by law or regulations. I also understand that one or more Providers and/or Insurers may receive payment from UCB for disclosing my Health Information for some or all of the purposes listed above.

I understand that this Authorization is voluntary and that I am not required to sign this Authorization. I may revoke this Authorization at any time (1) by mailing a letter, including my First Name, Last Name, Date of Birth, Gender, and ZIP Code, requesting such cancellation to UCBCares® at 1950 Lake Park Drive, Smyrna, GA 30080; or (2) by informing my Providers in writing that I do not want them to share any information with UCB. I understand that revoking my Authorization means my physicians, pharmacies, and health plans, as well as UCB, Inc., may no longer rely on the Authorization to use or disclose my Health Information, but it will not affect previous disclosures made by them pursuant to this Authorization. UCB shall provide timely notification of my revocation of this Authorization to my Providers and Insurers. Once my Providers and Insurers receive and process the notice of revocation of this Authorization, my Providers and Insurers may no longer make disclosures of my Health Information to UCB as permitted by this Authorization.

This Authorization expires 10 years from the date it was signed unless a shorter period is mandated by the law of my state of residence, or unless otherwise revoked as outlined above. I understand that I have the right to receive a copy of this Authorization once it is signed.

otherwise revoked as outlined above. I direct starta that they the right to	eceive a copy of this Authorization	/ /					
Patient Signature (Patient or Patient Representative)	Patient/Patient Representative Name	Date					
Court Appointed Guardian Power of Attorney (including for healt	ncare decisions) Other						
I agree to receive text messages from BIMZELX Navigate®. Message and data Text HELP for help. If you have questions, contact the BIMZELX Nurse Navigate	3 11 3	3 .					
I agree that I am a U.S. resident and give UCB permission to send me information or contact me and/or my healthcare provider regarding my disease as well as information on other related treatments, products, and services, and for marketing and informational purposes by phone, email, or mail. I understand that UCB will not sell my name, address, email address, or any other information to any other third party (other than UCB's agents, service providers, contractors, and representatives) for their own marketing use.							
I agree to receive communications from UCB (as defined above), including but not limited to calls made with an autodialer or prerecorded voice at the phone number(s) provided to provide me with insurance coverage and financial assistance resources and information, injection support, and for other non-marketing purposes. If I have designated a patient representative, he or she also agrees hereby to receive such communications from UCB for the purposes described above at the phone number(s) provided. I understand that I (and, if applicable, my patient representative) can opt out of these communications at any time by mailing a letter, including my First Name, Last Name, Date of Birth, Gender, and ZIP Code, requesting such cancellation to UCBCares at 1950 Lake Park Drive, Smyrna, GA 30080.							
		/					
Patient Signature (Patient or Patient Representative)	Patient/Patient Representative Name	Date					
Court Appointed Guardian Power of Attorney (including for healt	ncare decisions) Other Form	ore information on how UCB will use your information, please view our privacy policy at BIMZELX.com.					

For eligible, commercially insured patients only. With BIMZELX Navigate® Bridge, eligible patients whose insurance coverage is delayed or denied may receive BIMZELX for \$15 per dose for up to two (2) years or until the patient's coverage is approved, whichever comes first. Once coverage is approved, eligible patients will transfer to the BIMZELX Navigate® Savings program and receive BIMZELX for as little as \$5 per dose. View complete eligibility requirements and terms at BIMZELX.com/Patient-Support/Navigate-Benefits.

Please refer to the Medication Guide provided to you and discuss it with your doctor, or visit www.BIMZELX.com.

## For more information, contact BIMZELX Navigate®:

, ...,

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution, or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

